Material and Methods: Cell proliferation analysis was performed on human fibrosarcoma, liposarcoma, leiomyosarcoma and rhabdomyosarcoma cell lines with increasing doses of olaparib (0.25; 0.5; 1; 2; 4 μM) 3 h after cells seeding. The numbers of cells were assessed after 5 days and results normalized to the untreated control. For clonogenic assays, fibrosarcoma, liposarcoma, leiomyosarcoma and rhabdomyosarcoma cells were irradiated with 2, 4 or 6 Gy, with or without olaparib (1 µM) iniparib (10 µM) or veliparib (5μM) pre-treatment. The plating efficiency of the combined treatments were normalized to PARPitreated cells. The linear-quadratic survival expression was fitted to the data by nonlinear regression. The radiosensitization enhancement ratio for the PARPi at 50% survival (ER50) was as follows: ER50 = Dose at 50% survival without PARPi/Dose at 50% survival with PARPi. The impact of PARP inhibition on γ-H2Ax foci formation was evaluated in rhabdomyosarcoma cells treated with olaparib 1 μM after 48 h, and irradiated at 4 Gy. Cells were probed with primary antibody to γ-H2AX.
Purpose or Objective: Glioblastoma (GBM) is the most common primary brain tumor in adults. Despite intense treatment, including surgery and radiochemotherapy, prognosis is dismal with a median overall survival time of only 15 months. The vascular endothelial growth factor-A (VEGF-A) has been identified as one of the key regulators of neoangiogenesis in these highly vascularized tumors. Therefore, disruption of the VEGF-A signaling cascade by neutralizing VEGF-A and preventing ligation of its receptors appeared to be a promising approach for targeting neoangiogenesis. However, in recent phase III trials application of the VEGF-A blocking antibody bevacizumab in combination with radiochemotherapy failed to prolong overall survival in newly diagnosed GBM despite increasing progression-free survival and improving performance status. The aim of our study was to analyze the treatment effects of radiotherapy in combination with bevacizumab in a clinically relevant setting. Therefore, we established an orthotopic, syngeneic mouse glioblastoma model and subjected it to fractionated radiotherapy in combination with the bevacizumab mouse analogue G6-31.
Material and Methods: GL261 mouse GBM cells were stereotactically transplanted into the frontal lobe of C57/BL6 mice and tumors were allowed to grow for one week. Radiation therapy was performed with a Small Animal Radiation Research Platform (SARRP, Xstrahl) which incorporates contrast agent-CT (CA-CT)-based imaging followed by high precision radiation delivery. Fractionated irradiation with daily doses of 2 Gy up to a cumulative dose of 20 Gy was administered with or without accompanying VEGF-A blockade by the mouse bevacizumab analogue G6-31. Overall survival and tumor size were monitored, histological analyses, and transcriptomic profiling of tumor and normal tissue are currently being performed.
Results: Stereotactic implantation of GBM was successfully accomplished, fractionated irradiation was implemented by CA-CT-based image guidance, and tumor growth was successfully monitored by serial CA-CT scans. The single agent treatments led to a significant delay in tumor growth and prolongation of survival as compared to the sham-treated controls. Importantly, the strongest therapeutic effects were observed with the combined treatment. Histological details, including vessel density and structure, as well as markers of cell death induction, and transcriptomic profiling of tumor and normal tissue are currently under investigation.
Conclusion: This pilot study shows that syngeneic, orthotopic glioblastoma transplants combined with stereotactically delivered radiotherapy are feasible and clinically relevant in vivo models for evaluating the therapeutic efficacy of multimodal treatment approaches based on fractionated irradiation. Material and Methods: For MC simulation, TOPAS v.b-12 was used. GNPs of 50 and 100 nm diameter were tested. GNP cluster morphology was approximated as a body center cubic by placing 8 GNPs at the corner and one at the centered of a 2 × 2 × 2 μm³, 1 × 1 × 1 μm³, 0.5 × 0.5 × 0.5 μm³, or 0.25 × 0.25 × 0.25 μm³ (for 100 nm GNP) or 0.18 × 0.18 × 0.18 μm³ (for 50 nm GNP) cube located in a 4 × 4 × 4 μm³ water filled cube phantom. 4 μm × 4 μm square shaped beams of spectrum-energetic 50, 100 kVp photons and 70, 170 MeV protons were irradiated to the water filled cube phantom with GNPs in it. We computed the distribution of secondary electrons as a function of distance from the surface of the GNP at the cube center and calculated the ratio (SER) together with dose enhancement ratio (DER) for 4 different cubes geometries. For scoring particles,10 nm width of concentric shell shaped detector was constructed up to 100 nm from the center point of the cube. 10E8 histories of protons and 2 × 10E10 histories of photons were used for simulation. All counted values at each detector were summed to obtain the total dose and secondary electrons in a sphere of 100 nm radius and were normalized to 2 × 2 × 2 μm³ cube morphology.
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Results: DER and SER increase as the distance of the GNPs reduces. The largest DER as well as SER was obtained for 0.25 × 0.25 × 0.25 μm³ cube for 100 nm 0.18 × 0.18 × 0.18 μm³ for 50 nm GNP. In case of 50 nm GNPs, DER increment was 1.421, 1.396, 1.017, and 1.014 for 50 kVp, 100 kVp photons, 70 MeV and 170 MeV protons, respectively. SER increment was 1.319, 1.303, 1.021, and 1.018, for 50 kVp, 100 kVp photons, 70 MeV and 170 MeV protons, respectively. For 100 nm GNPs, we observed the qualitatively same results but increment ratio was larger for all tested radiations.
Conclusion:
As shown in this study, DER with GNPs was larger when they are closely packed in the phantom. Therefore, better therapeutic effects can be expected with close-packed GNPs. Material and Methods: Firstly, to verify the imaging detectability of Fe3O4/TaOx nano particles, in-vivo tests were conducted. Approximately 600 mg/kg of19 nm diameter Fe3O4/TaOx nano particles dispersed in phosphate buffered saline (PBS) were injected to ten nude Balb/c mice through the tail vein. Mico-CT (Simens Inveon) was scanned for 5 mice and MRI (BioSpec, 70/20 USR, BRUKER Co.) scan was conducted for rest of mice. For both imaging, 4 consecutive scanning was performed at pre-and post-injection (5 min, 30 min, and 1 hour). Difference between pre-and post-injection images was analyzed by computing the pixel histogram and correlation coefficient factor using MATLAB in the user defined ROI (region of interests) . Secondly, to quantify the potential therapeutic enhancement with nano materials, DER (Dose Enhancement Ratio) and number of SER (Secondary Electron Ratio) were computed using MC simulation . Diameter of 19 nm circular beams of mono-energetic 10 MeV, 70 MeV, 150 MeV protons were irradiated to a Gold(Au), Tantalum(Ta), TaOx, Fe3O4/TaOx (core / shell), and Fe3O4 nano particle located at the center of 4 × 4 × 4 μm³ water filled cube phantom. DER and SER were computed by placing a 1 nm thickness of shell detector at the surface of the particle.
Results:
In CT, MRI imaging, the aorta, the blood vessel, and the liver were clearly visualized after intravenous injection of Fe3O4/TaOx nano particles. There was large different between pre and post-injection images of Histogram data and Coefficients of correlation factor in CT and MR are 0.006, 0.060, respectively. When 10 MeV protons were irradiated for a Gold(Au), Tantalum(Ta), TaOx, Fe3O4/TaOx, Fe3O4 nano particle, DER was 9. 089, 7.724, 4.424, 3.660 and 3.255 respectively. Similarly, SER increment was 9. 629, 8.401, 5.060, 4.341, and 3.590 for Gold(Au), Tantalum(Ta), TaOx, Fe3O4/TaOx, Fe3O4 nano particle, respectively. For 70 MeV proton beams, DER was similar to those for 10 MeV, but increment ratio was lower for 150 MeV protons.
Conclusion: Fe3O4/TaOx nano particles have potential as a multifunctional agent which enhances the accuracy in cancer detection through visualization of developed tumor lesion and increases the therapeutic effect in proton therapy. The dose enhancement with Fe3O4/TaOx was estimated as half of the Gold. However, tumor targeting such as combined with magnetic field may overcome the low DER
